IP News Bulletin for Japan and China, June 2026

The IP News Bulletin for Japan and China, June 2026, published by www.patents.jp, reveals a transformative period for intellectual property in East Asia, anchored by China's introduction of up to 6-year drug trial data exclusivity and a landmark Japanese patent term extension ruling.

What recent developments shape the Japan and China IP landscape?

In China, the National Medical Products Administration (NMPA) issued its Implementation Measures for Drug Trial Data Protection, taking immediate effect to provide up to 6-year exclusivity for innovative drugs. Separately, the CNIPA white paper "China's Intellectual Property Protection Status in 2025" confirmed China's entry into the WIPO Global Innovation Index top 10, reported 6.318 million valid invention patents, and highlighted a landmark RMB 53.35 million damages award in a plant variety case. In Japan, the JPO annual survey on patent application technologies revealed Japanese leadership in fusion power generation, low-carbon fuel engines, lactic-acid bacteria food, and cyber detection technologies.

What is the strategic impact for pharmaceutical and technology rights holders?

For pharmaceutical executives, the up to 6-year data exclusivity in China represents a landmark shift, providing a powerful incentive to prioritize innovative drug launches in the Chinese market. The bulletin highlights the Toray v Sawai ruling as a landmark development for patent term extensions and damages in Japan, signaling a maturing enforcement landscape. The Zoom Video Communications case reinforces that trademark infringement carries substantial financial liability — 166 million JPY — in Japan, even when widespread public recognition limits the availability of injunctive relief. Asahi Kasei's enforcement actions in Shanghai demonstrate growing confidence in Chinese IP courts for high-tech chemical patent litigation.

Frequently Asked Questions

What is the data exclusivity duration for innovative drugs in China?

Up to 6 years, as introduced by the NMPA's Implementation Measures for Drug Trial Data Protection issued on May 15, 2026.

Why did the Tokyo District Court deny an injunction against Zoom Video Communications?

The court determined that widespread public recognition of the Zoom meeting platform after 2020 reduced the likelihood of consumer confusion, although it awarded approximately 166 million JPY in damages for trademark infringement.

What specific technology areas did the JPO's 2026 patent survey examine?

The survey focused on four areas: fusion power generation, low-carbon fuel engines, lactic-acid bacteria food, and cyber detection technologies.